Dearborn Partners LLC Purchases Shares of 23,988 Zoetis Inc. $ZTS

Dearborn Partners LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 23,988 shares of the company’s stock, valued at approximately $1,724,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares in the last quarter. Empowered Funds LLC increased its position in shares of Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC raised its stake in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC raised its stake in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Glenview Trust co lifted its position in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ZTS shares. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Barclays lowered their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. TD Cowen reduced their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday. Stifel Nicolaus decreased their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research note on Thursday, August 20th. Finally, UBS Group decreased their price target on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $107.43.

Zoetis Stock Performance

Shares of Zoetis stock opened at $74.99 on Friday. The company has a market cap of $30.99 billion, a P/E ratio of 12.35, a PEG ratio of 1.81 and a beta of 0.74. The business has a 50-day moving average price of $75.59 and a two-hundred day moving average price of $95.75. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter last year, the firm posted $1.76 EPS. The company’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.